From wiki-pain
Revision as of 05:30, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 1996
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 3
Disease Relevance 1.60
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
lung 1
SCLC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Serotonin 2 100.00 Very High Very High Very High
cytokine 12 88.00 High High
agonist 3 80.96 Quite High
Sumatriptan 3 76.16 Quite High
antagonist 4 68.24 Quite High
Potency 1 65.12 Quite High
Opioid 1 50.24 Quite High
Central nervous system 1 5.00 Very Low Very Low Very Low
anesthesia 1 5.00 Very Low Very Low Very Low
Inflammation 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Small Cell Lung Cancer 22 100.00 Very High Very High Very High
Lung Cancer 2 100.00 Very High Very High Very High
Syndrome 34 99.78 Very High Very High Very High
Death 1 89.72 High High
Apoptosis 3 86.12 High High
Cytomegalovirus Infection 20 76.40 Quite High
Cancer 15 36.04 Quite Low
Necrosis 2 27.76 Quite Low
Skin Cancer 2 5.00 Very Low Very Low Very Low
Neurological Disease 1 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We previously reported a significant mitogenic effect of serotonin (5-hydroxytryptamine, 5-HT) on human small-cell lung carcinoma cells (SCLC, GLC-8), mediated by both 5-HT1D and 5-HT1A receptors.
Regulation (effect) of SCLC in lung associated with lung cancer, small cell lung cancer and serotonin
1) Confidence 0.21 Published 1996 Journal Eur. J. Pharmacol. Section Abstract Doc Link 9016944 Disease Relevance 0.28 Pain Relevance 0.39
after stimulation with HuDmix in Hu-PNS patients, SCLC and healthy controls.
Regulation (controls) of SCLC associated with syndrome and small cell lung cancer
2) Confidence 0.14 Published 2007 Journal Cancer Immunol Immunother Section Body Doc Link PMC1914259 Disease Relevance 0.70 Pain Relevance 0.12
Together, these results show that naltrindole is a new inhibitor of the Akt/PKB signaling pathway, suggesting that naltrindole could be a potential lead for the development of a new type of inhibitors that target the constitutively active Akt/PKB signaling-dependent SCLC cells.
Regulation (target) of SCLC associated with small cell lung cancer
3) Confidence 0.07 Published 2004 Journal Cancer Res. Section Abstract Doc Link 15574783 Disease Relevance 0.62 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools